Update in Management Strategies of Chronic Myeloid Leukemia

Nahla A M Hamed
Additional contact information
Nahla A M Hamed: Hematology Department, Faculty of Medicine, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2020, vol. 16, issue 5, 90-93

Abstract: The goal of CML treatment in the recent era is to discontinue medication for treatment free remission after achieving a stable deep molecular response. A prerequisite for TKI discontinuation is the assessment of the remaining tumor load by standardized molecular monitoring using high quality quantitative PCR by the international scale. Molecular monitoring post-treatment suspension is also imperative for CML patients attempting TFR.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555949.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555949.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:16:y:2020:i:5:p:90-93

DOI: 10.19080/CTOIJ.2020.16.555949

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().